# A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors

> **NCT05298592** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 77 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **BIOLOGICAL:** BMS-986406
- **BIOLOGICAL:** Nivolumab
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT05298592
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-31
- **Primary completion:** 2024-08-16
- **Final completion:** 2024-08-16
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2024-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05298592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05298592, "A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors". Retrieved via AI Analytics 2026-08-21 from https://api.ai-analytics.org/clinical/NCT05298592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*